Head-To-Head Contrast: Mirna Therapeutics (SYBX) versus Its Peers
Mirna Therapeutics (NASDAQ: SYBX) is one of 45 public companies in the “Biopharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Mirna Therapeutics to similar businesses based on the strength of its institutional ownership, valuation, analyst recommendations, earnings, risk, dividends and profitability.
This table compares Mirna Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Mirna Therapeutics Competitors||-13,545.52%||260.78%||-20.28%|
Earnings & Valuation
This table compares Mirna Therapeutics and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Mirna Therapeutics Competitors||$579.33 million||$241.73 million||-6.56|
Mirna Therapeutics’ peers have higher revenue and earnings than Mirna Therapeutics. Mirna Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Volatility & Risk
Mirna Therapeutics has a beta of 3.59, meaning that its stock price is 259% more volatile than the S&P 500. Comparatively, Mirna Therapeutics’ peers have a beta of 1.24, meaning that their average stock price is 24% more volatile than the S&P 500.
Insider and Institutional Ownership
44.6% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 18.6% of Mirna Therapeutics shares are held by insiders. Comparatively, 14.0% of shares of all “Biopharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This is a summary of recent recommendations for Mirna Therapeutics and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Mirna Therapeutics Competitors||193||912||1692||67||2.57|
Mirna Therapeutics currently has a consensus price target of $19.50, suggesting a potential upside of 2.55%. As a group, “Biopharmaceuticals” companies have a potential upside of 7.75%. Given Mirna Therapeutics’ peers stronger consensus rating and higher possible upside, analysts clearly believe Mirna Therapeutics has less favorable growth aspects than its peers.
Mirna Therapeutics peers beat Mirna Therapeutics on 8 of the 11 factors compared.
About Mirna Therapeutics
Synlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions, including inflammatory bowel disease , cancer and metabolic conditions, such as diabetes and obesity. The Company’s synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company’s pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU.
Receive News & Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.